CJC-1295 (No DAC) combined with Ipamorelin is a synergistic peptide blend widely utilized in research settings to study pulsatile growth hormone (GH) secretion and hypothalamic–pituitary axis signaling. This combination is designed to evaluate the interaction between growth hormone–releasing hormone (GHRH) analogs and selective ghrelin receptor agonists in controlled laboratory environments.
 
CJC-1295 (without DAC) functions as a short-acting GHRH analog, commonly studied for its ability to promote natural GH pulse amplification without prolonged receptor binding. Ipamorelin, a selective growth hormone secretagogue, is researched for its targeted stimulation of GH release with minimal interaction with cortisol or prolactin pathways.
 
Together, this peptide combination is frequently investigated for its role in metabolic signaling, tissue repair models, body composition research, recovery pathways, and age-related endocrine decline studies. The absence of DAC allows researchers to observe precise, time-dependent GH signaling dynamics.
 
This formulation is produced to meet high-purity laboratory standards and is intended exclusively for analytical, in-vitro, and experimental research applications.
 
For research use only. Not for human consumption.